Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA

Ratings ESG MSCI

Ratings Cytokinetics, Incorporated: Strengths and Weaknesses

Highlights: Cytokinetics, Incorporated
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses: Cytokinetics, Incorporated
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Rating Financials

Cytokinetics, Incorporated SectorUnited States

Fundamentals

-

Growth

Revenue growth

EPS growth

FCF growth

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

-

ROA

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Cytokinetics, Incorporated SectorUnited States

Global Valuation

-

Enterprise value

-

EV/Revenue

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

More ratings

Rating Consensus

Cytokinetics, Incorporated SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Cytokinetics, Incorporated SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Cytokinetics, Incorporated SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
9.29B -
AA
- -
54.5B
A
41.73B
AAA
21.87B - - - -
21.47B -
A
- -
15.79B
AAA
15.29B
A
13.32B
BB
11.53B -
AA
- -
11.09B - - - -
Average 21.59B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. CYTK Stock
  4. Ratings Cytokinetics, Incorporated
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
BENEFIT NOW